-related genetic counseling and testing . J Genet Couns 2020 ; 29 : 518 – 529 . 32291871 8. Meghani SH , Byun E , Gallagher RM . Time to take stock: a meta-analysis and systematic review of analgesic treatment disparities for
Search Results
Presenters: Shonta Chambers, Elizabeth Harrington, Lisa A. Lacasse, Robert Winn, and moderated by Alyssa A. Schatz
dedicated to empowering patients. By expanding the availability of this information, it will increase awareness in genetic testing, share tools for a more proactive approach to health, and provide greater access to genetic counseling and testing, ultimately
Presenter: Julio M. Pow-Sang
/or potential risk of cancer in family members. If these criteria are met, germline multigene testing should include at least BRCA1 , BRCA2 , ATM , PALB2 , CHEK2 , MLH1 , MSH2 , MSH6 , and PMS2 . Posttest genetic counseling is strongly recommended if
.2013 to Version 1.2015 to reflect the most recent updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer. This update includes many important changes and additions, such as addressing genetic counseling as part of
Shu Fen Wong, Richard Norman, Trisha Lynette Dunning, David Michael Ashley, Mustafa Khasraw, Theresa Margaret Hayes, Ian Collins, and Paula Kate Lorgelly
-stage breast cancer changed their preferences after a medical consultation. Choice-based techniques such as discrete choice experiments (DCE) 4 have been successfully used to evaluate genetic counseling for cancer, 5 screening programs, 6 and cancer
example in a condition known as ‘mosaicism,’ in which the mutation is not present in all of the cells of the body). Because of this, the NCCN Guidelines continue to highlight the critical importance of genetic counseling for patients prior to undergoing
Mary B. Daly, Robert Pilarski, Michael Berry, Saundra S. Buys, Meagan Farmer, Susan Friedman, Judy E. Garber, Noah D. Kauff, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Shaveta Vinayak, Nicoleta C. Voian, Jeffrey N. Weitzel, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, and Susan Darlow
mother and/or father. 1 , 2 An individual suspected of being at risk for hereditary cancer should be offered genetic counseling. 3 , 4 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast
Sheetal Kircher, Nicole Braccio, Kathleen Gallagher, Ruth Carlos, Lynne Wagner, Mary Lou Smith, Alan Balch, and Al B. Benson III
cancer care continuum, including navigation, chemotherapy toxicity management, genetic counseling, clinical trial enrollment, mental health services, survivorship care, and palliative care ( Figure 1 ). 6 – 8 Guidelines need to evolve to offer evidence
Eve Henry, Victor Villalobos, Lynn Million, Kristin C. Jensen, Robert West, Kristen Ganjoo, Alexandra Lebensohn, James M. Ford, and Melinda L. Telli
these NCCN Guidelines, visit NCCN.org ). 17 The NCCN Guidelines also recommend genetic counseling for patients who are considering p53 testing. 17 A multidisciplinary approach with professional geneticists, counselors, psychologists, and oncologists
Deborah K. Armstrong
genetic counseling with “strong consideration” for genetic testing, she said. Due to their efficacy in ovarian cancer and some other malignancies, the use of PARP inhibitors has steadily grown since 2014, when olaparib was approved. At the time of Dr
